Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Supernus
Biotech
Supernus’ stocks down again, despite positive phase 3 ADHD data
Supernus’ two phase 3 studies in children with ADHD hit their primary endpoints but didn’t wow investors worried about established generics.
Conor Hale
Dec 6, 2018 11:23am
Supernus adds epilepsy drug via $185M Biscayne buy
Sep 14, 2018 9:45am
Supernus clears PhII ADHD drug hurdle, but shares drip downward
Oct 11, 2016 11:40am
